



Myriad Genetics, Inc.
 Investor Relations Department
 320 Wakara Way
 Salt Lake City, UT 84108
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: MYGN	
Last Trade:	31.53
Trade Time:	11:53 AM ET Dec 11, 2017
Change:	-2.21 ▼ (-6.550%)
Day Range	31.49 - 33.64
52-Week Range	15.15 - 37.30
Volume	369,752

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Why Invest in Myriad Genetics

Myriad's 9 molecular diagnostic tests provide a preeminent market position today; with revenue up 23% in FY2012 our 13 innovative pipeline tests will ensure Myriad's continued growth for the future. Th... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 8, 2017*
[Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium](#)
- Dec 6, 2017*
[Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium](#)
- Nov 10, 2017*
[Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Health Outcomes for Veterans](#)
- Nov 9, 2017*
[Myriad Genetics to Present at the 2017 Jefferies London Healthcare Conference](#)
- Nov 7, 2017*
[Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Aug 9, 2017*
[Annual Report \(10-K\)](#)
- Oct 11, 2016*
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Feb 8, 2017*
[Quarterly Report \(10-Q\)](#)